Syngene International Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ohdnsfftk1v00aksfpo57aio.pdf

Key Takeaways


The Librela Overhang: Sizing the Hole

Bains: "Getting back to more sustainable growth and to higher growth levels is clearly the direction that we're looking to build Syngene. The Librela headwinds have clearly had material impacts last year '26... And we would expect to end '27 on a growth trajectory and the Librela effect will then have washed out."

Margin Mechanics: The Beat and the Path Forward


New Capabilities and Facilities: The Build Phase


The BMS Anchor and CDMO Ambition

Bains: "I think it's really -- the time horizon enables strategic thinking. And of course, if we look at the market outside and developments in these new modalities that we've discussed... it really allows the parties, Bristol-Myers Squibb and Syngene to think strategically."

Leadership and Strategic Reset

Mazumdar-Shaw: "I'm someone who has worked with them very closely for over many, many years. Obviously, I'm happy to be back to take Syngene through this very exciting time. And this is a team I'm very familiar with, and I'm very confident that we will reset and rebuild the Syngene model in all the particular areas that we spoke about."

External Risks: Tariffs, Middle East, and Cost Pass-Through


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthBroadly flat performanceFY27
H1 vs H2 weightingH1 muted; H2 meaningfully stronger as new contracts ramp upFY27
Q1 Librela impactMore pronounced adverse impact of destockingQ1 FY27
Librela volumesAlmost no Librela in Q1 and Q2; minor volumes toward year-endFY27
Librela exitLibrela effect fully washed out; exit year on a growth trajectoryEnd of FY27
EBITDA marginMid-20s, with Bayview costs baked inFY27
Stronger growthHealthy deal pipeline translates into stronger growthFY28 onwards
Bayview biologicsMoving toward operationalization; initial trial runs expectedFY27
BMS contractExtended through 2035; growth around US inflation at some level10-year horizon

Key Metrics

MetricQ4 FY26
Revenue from operations₹1,037 cr, +2% YoY and +13% QoQ
Full year revenue growth3% YoY
Underlying revenue growth ex-LibrelaHigh-single digits (FY26)
Operating EBITDA₹303 cr, margin 29% vs 34% in Q4 FY25
Full year operating EBITDA margin25%
Profit after tax before exceptional items₹153 cr, down 16% YoY
Reported profit after tax₹148 cr, down 19% YoY, after ₹25 cr termination benefits and ₹20 cr gratuity credit
Free cash flow₹521 cr (FY26)
Net cash balance₹1,800 cr as of March 31, 2026
Revenue split59% research services, 41% CDMO (Q4); full year approx two-thirds CRO, one-third CDMO
FY27 revenue guidanceBroadly flat
FY27 EBITDA margin guidanceMid-20s
Q4 capex$10M, approx 50% research services, 40% CDMO, rest digitization/automation/infrastructure
Q4 normalized effective tax rate24.2% vs 23.7% in Q4 FY25